United States of America– [28-January-2026]

The bioproduction market encompasses the manufacturing of biologics, biosimilars, vaccines, cell and gene therapies, and nucleic acid therapeutics. Driven by rising demand for biosimilars, automation, and advanced manufacturing solutions, the market is expanding rapidly, with applications across cancer, autoimmune, and rare diseases.

Market Size ,Share And Trends

According To The Insight Partners, The global bioproduction market is projected to grow from US$ 22.34 billion in 2022 to US$ 63.39 billion by 2030, registering a CAGR of 13.9% during the forecast period, driven primarily by the rising demand for biosimilars and the increasing adoption of automation in cell and gene therapy manufacturing.

Biosimilars: Expanding Access and Driving Market Growth

One of the major factors fueling market growth is the patent expiry of blockbuster biologics, which opens opportunities for biosimilars. Biosimilars are cost-effective alternatives to reference biologics and are increasingly used in the treatment of cancer, autoimmune disorders, and other chronic conditions. For instance, biosimilars of trastuzumab, a targeted therapy for breast and stomach cancer, such as Herzuma and Ontruzant, have improved affordability and accessibility for patients. The introduction of new biosimilars is encouraging competition among manufacturers, prompting investments in scalable bioproduction processes. As more originator biologics reach the end of their patent life over the next decade, the demand for biosimilars is expected to grow exponentially, driving expansion in manufacturing capacity and technological adoption.

Get A Pdf Copy@ https://www.theinsightpartners.com/sample/TIPRE00030322

Automation in Bioproduction: Improving Efficiency and Consistency

Automation is another critical driver shaping the future of bioproduction. Traditional manual manufacturing methods in cell and gene therapy are labor-intensive and prone to variability, contamination, and high production costs. Automated platforms, such as Lonza’s Cocoon and Miltenyi Biotec’s CliniMACS Prodigy, allow for the seamless execution of multiple production steps with minimal human intervention. These systems improve process consistency, reduce contamination risks, and enable large-volume production, which is essential for commercializing cell therapies like CAR-T and gene-modified cell therapies.

Furthermore, software solutions such as GE Healthcare’s Chronicle support full digital workflow integration for cell therapy manufacturing. These tools provide GMP-compliant data tracking, process optimization, and real-time analytics, helping biopharmaceutical companies reduce operational inefficiencies and enhance regulatory compliance.

Frequently Asked Questions

Q1. What is driving the growth of the global bioproduction market?
A: The market is driven by rising demand for biologics, advancements in cancer treatment, rapid development of gene and cell therapies, and increasing adoption of biosimilars.

Q2. How fast is the bioproduction market expected to grow?
A: The market is projected to grow from US$ 22.34 billion in 2022 to US$ 63.39 billion by 2030, registering a CAGR of 13.9%, supported by innovation and expanding therapeutic applications.

Q3. Why is oncology a key application area in bioproduction?
A: Oncology drives significant demand due to the growing use of monoclonal antibodies, immunotherapies, and biosimilars, which require advanced bioproduction capabilities.

Market Segmentation and Regional Insights

The growth in biosimilars and automation is reflected across various market segments:

By Product: Biologics and biosimilars dominate the market, while cell and gene therapies are the fastest-growing segments due to rising therapeutic innovations.
By Application: Cancer treatments hold the largest share, supported by biosimilar adoption in oncology.
By Equipment: Consumables and accessories account for the largest share, driven by recurring demand in automated workflows.
By End User: Biopharmaceutical companies remain the primary consumers, while contract manufacturing organizations (CMOs) are witnessing the highest growth as outsourcing becomes crucial for scalable production.
By Geography: North America currently leads the market, supported by advanced research infrastructure and regulatory support, while Asia Pacific is emerging as the fastest-growing region due to increasing investments in healthcare and biotechnology.
Top Key Player

Thermo Fisher Scientific Inc – Offers integrated bioproduction solutions, including cell culture media, bioreactors, and automation platforms, supporting both research and large-scale manufacturing.
Merck KGaA – Provides equipment and reagents for upstream and downstream processing, with a focus on biopharmaceutical process optimization and digital manufacturing.
Hoffmann-La Roche Ltd – Focused on biologics and biosimilars, Roche invests in innovative production technologies and strategic partnerships to improve global access to therapies.
Bio-Rad Laboratories Inc – Specializes in high-quality reagents, consumables, and laboratory equipment, supporting cell culture and bioproduction processes.
Lonza Group AG – Offers automated platforms for cell and gene therapy production, such as the Cocoon system, and provides contract manufacturing services for large-scale biologics.
bbi-biotech GmbH – Provides bioreactor systems, single-use technologies, and upstream processing solutions for efficient and scalable production.
Danaher Corp – Offers equipment, consumables, and analytical instruments for upstream and downstream bioproduction, emphasizing workflow optimization and automation.
Future Outlook

The global bioproduction industry is expected to benefit from synergistic growth in biosimilar adoption and automation. Investment in next-generation manufacturing facilities, digital workflow integration, and collaborative research initiatives will accelerate market expansion. Regulatory support, technological innovation, and the push for cost-effective therapies will continue to drive global adoption. By 2030, bioproduction is poised not only to scale commercially but also to play a crucial role in improving patient access to advanced biologics and personalized therapies worldwide

About The Insight Partners

The Insight Partners delivers market intelligence and consulting services to help clients make informed decisions. The firm covers industries such as Aerospace and Defense, Automotive and Transportation, Semiconductor and Electronics, Biotechnology, Healthcare IT, Manufacturing, Medical Devices, Technology, Media, and Chemicals and Materials.

 

Contact Information:
Email: [email protected]
Website: www.theinsightpartners.com
Phone: +1-646-491-9876

Also Available in :

Korean German Japanese French Chinese Italian Spanish